The New Benchmark: Novo Nordisk’s CagriSema Outshines Semaglutide in Phase 3 Diabetes Trial

Novo Nordisk has announced headline results from the REIMAGINE-2 Phase 3 trial, positioning its investigational once-weekly therapy, CagriSema, as a formidable successor to the current standard of care. The trial demonstrated that CagriSema provides superior blood sugar control and weight reduction in adults with type 2 diabetes compared to the company’s blockbuster semaglutide (Ozempic/Wegovy) alone.

REIMAGINE-2: The Data at a Glance

The 68-week trial involved 2,728 adults with type 2 diabetes whose blood sugar was inadequately controlled on metformin. The results show a clear “step up” in efficacy by combining two different metabolic hormones.

Key Clinical Outcomes (68 Weeks):

HbA1c Reduction: CagriSema achieved a superior reduction of 1.91 percentage points (from a baseline of 8.2%), compared to 1.76 for semaglutide.
Significant Weight Loss: Patients on CagriSema lost an average of 14.2% of their body weight, significantly outperforming the 10.2% lost by those on semaglutide.
Depth of Response: 43% of participants on CagriSema achieved a weight loss of 15% or more, while nearly a quarter (24%) reached the 20% threshold.

“By targeting multiple pathways simultaneously, we are seeing outcomes that go beyond what each therapy can achieve individually,” stated Martin Holst Lange, Executive VP of R&D at Novo Nordisk.

How it Works: The Amylin + GLP-1 “Synergy”

Unlike current “dual agonists” (like Eli Lilly’s Mounjaro) that target GLP-1 and GIP, CagriSema uses a unique dual-mechanism:

Semaglutide (GLP-1): Mimics a gut hormone to stimulate insulin, suppress glucagon, and slow stomach emptying.
Cagrilintide (Amylin Analogue): Mimics a pancreatic hormone that acts on the brain to increase the feeling of fullness and decrease cravings.

This combination creates what researchers call a “Semaglutide-squared” effect, tackling both the physiological and neurological drivers of hunger.

Market Impact & Next Steps

Industry analysts note that while CagriSema did not reach the ambitious 25% weight loss target some investors hoped for in non-diabetic populations, its 14.2% loss in diabetics is exceptionally high, as weight loss is traditionally much harder to achieve in this group.

Regulatory Status: Novo Nordisk filed for FDA approval for weight management in late 2025; they now plan to approach authorities to discuss the path forward for the Type 2 Diabetes indication.
Manufacturing Challenge: Because the two drugs cannot be mixed in a single solution, CagriSema requires a dual-chamber pen technology, which Novo is currently scaling for mass production.